Showing results (1491-1500 of 1,514) with videos related to
Sort By:
Pageof 152
International Journal of Stroke : Official Journal of the International Stroke Society|January 22, 2026
Sex Differences in Mortality and Functional Outcomes Across Stroke Subtype: A Nationwide Cohort StudyTae Jung Kim, Ji Sung Lee, Jun Yup Kim, et al.Cancer Research and Treatment|July 4, 2023
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean SubsetKi Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.The Oncologist|August 26, 2015
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck CancerKeun-Wook Lee, Youngil Koh, Sung-Bae Kim, et al.Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 5, 2019
Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint InhibitorsBhumsuk Keam, Chang Kyung Kang, Kang Il Jun, et al.The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase InhibitorsByoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.Pageof 152